Investors seeking early exposure to innovative life sciences companies will have a direct line to management teams at the upcoming Life Sciences Virtual Investor Forum on September 17, 2026. Hosted by Virtual Investor Conferences and marketed by B2i Digital, Inc., the online event will feature seven companies presenting live, 30-minute sessions followed by audience Q&A. The forum’s emphasis on interactive dialogue and its diverse lineup of therapeutic areas underscore the growing importance of specialized investor conferences in connecting capital with emerging science.
The presenting companies reflect a wide range of high-impact medical needs. Sona Nanotech Inc. is developing a photothermal cancer therapy based on gold nanorods, while Raphael Pharmaceutical focuses on cannabinoid-based formulations for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease. Amplia Therapeutics Ltd. brings a pipeline of Focal Adhesion Kinase inhibitors targeting cancer and fibrosis. Adaptin Bio, Inc. is advancing precision drug delivery technologies, including approaches to cross the blood-brain barrier. Acurx Pharmaceuticals, Inc. is working on a new class of antibiotics for infections caused by priority pathogens. CytoDyn Inc. is studying a humanized monoclonal antibody in solid-tumor oncology. 4DMedical Ltd. offers FDA-cleared four-dimensional respiratory imaging. These presentations provide investors with a window into cutting-edge research that could reshape treatment paradigms.
For investors, the forum’s live Q&A format is a key differentiator. "Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind," said David Shapiro, Chief Executive Officer of B2i Digital, Inc. This direct engagement allows investors to assess management’s responsiveness and strategic clarity—insights that static reports often miss.
The event is free to register, and replays will be available on the B2i Digital and OTC Markets YouTube channels. Detailed event information and presenting company profiles can be found at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum. Investors can register at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC. B2i Digital’s media network spans over 800 outlets with a combined monthly audience exceeding 330 million, amplifying the reach of presenting companies. For more information on B2i Digital’s programs, visit b2idigital.com.
The forum’s global lineup—companies from the NYSE, Nasdaq, TSX, ASX, and OTC Markets—highlights the international scope of life sciences innovation. As drug development costs rise and timelines stretch, events like this offer a cost-effective way for companies to engage a broad investor base and for investors to diversify across promising sectors. The emphasis on real-time interaction and on-demand replays further democratizes access, potentially accelerating the flow of capital to therapies that address unmet medical needs.
